Published in Brain Res on January 13, 2014
Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. Br J Clin Pharmacol (2015) 0.97
Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. Neural Regen Res (2014) 0.95
Driving neural regeneration through the mammalian target of rapamycin. Neural Regen Res (2014) 0.87
Cutting through the complexities of mTOR for the treatment of stroke. Curr Neurovasc Res (2014) 0.86
Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Ann Med (2014) 0.82
Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. Curr Neurovasc Res (2016) 0.75
RNF146 Inhibits Excessive Autophagy by Modulating the Wnt-β-Catenin Pathway in Glutamate Excitotoxicity Injury. Front Cell Neurosci (2017) 0.75
Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid. J Neuroinflammation (2017) 0.75
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J (2000) 41.48
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Autophagy fights disease through cellular self-digestion. Nature (2008) 33.83
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature (2006) 24.39
Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature (2006) 21.40
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
How to interpret LC3 immunoblotting. Autophagy (2007) 12.30
Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr (2007) 5.75
Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem (2006) 5.39
Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov (2012) 5.26
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell (2010) 5.09
Regulation of brain type II Ca2+/calmodulin-dependent protein kinase by autophosphorylation: a Ca2+-triggered molecular switch. Cell (1986) 4.27
Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab (2011) 3.57
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem (1990) 3.40
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med (2004) 3.26
Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab (2007) 3.10
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun (1991) 3.04
Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. Am J Pathol (2008) 2.57
Mechanisms of ischemic brain damage. Neuropharmacology (2008) 2.40
Calcium, ischemia and excitotoxicity. Cell Calcium (2010) 2.38
Characterization of a calmodulin kinase II inhibitor protein in brain. Proc Natl Acad Sci U S A (1998) 2.27
CaMKII regulation in information processing and storage. Trends Neurosci (2012) 1.96
Characterization of Ca2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. J Biol Chem (1994) 1.94
Activation of the multifunctional Ca2+/calmodulin-dependent protein kinase by autophosphorylation: ATP modulates production of an autonomous enzyme. Proc Natl Acad Sci U S A (1986) 1.87
Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell (2007) 1.86
Autophagy and apoptosis: what is the connection? Trends Cell Biol (2011) 1.81
Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol (2007) 1.75
CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci (2010) 1.49
Beclin 1-independent autophagy contributes to apoptosis in cortical neurons. Autophagy (2011) 1.42
Inhibitors of calmodulin-dependent protein kinase are nonspecific blockers of voltage-dependent K+ channels in vascular myocytes. J Pharmacol Exp Ther (1999) 1.35
CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem (2010) 1.28
The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin (2009) 1.27
Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab (2011) 1.18
Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem (2010) 1.18
Excitotoxic neuroprotection and vulnerability with CaMKII inhibition. Mol Cell Neurosci (2011) 1.18
Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca2+ channels. Mol Pharmacol (1992) 1.17
Lysosome dysfunction triggers Atg7-dependent neural apoptosis. J Biol Chem (2010) 1.16
Autophagy and protein aggregation after brain ischemia. J Neurochem (2010) 1.15
Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr Mol Med (2004) 1.11
Autophagic neuron death in neonatal brain ischemia/hypoxia. Autophagy (2008) 1.10
CaMKII in cerebral ischemia. Acta Pharmacol Sin (2011) 1.04
Neuronal autophagy in cerebral ischemia--a potential target for neuroprotective strategies? Pharmacol Rep (2012) 1.03
Autophagy in acute brain injury: feast, famine, or folly? Neurobiol Dis (2010) 1.01
Ca2+/calmodulin-dependent protein kinase II inhibitors disrupt AKAP79-dependent PKC signaling to GluA1 AMPA receptors. J Biol Chem (2010) 0.89
A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One (2012) 0.89
Neuroprotection in metabolism-based therapy. Epilepsy Res (2011) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
Autophagy in cancer: good, bad, or both? Cancer Res (2006) 2.66
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res (2012) 2.14
A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy (2011) 2.02
CaMKII regulation in information processing and storage. Trends Neurosci (2012) 1.96
Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell (2007) 1.86
Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy (2012) 1.86
Autophagy and apoptosis: what is the connection? Trends Cell Biol (2011) 1.81
Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci (2011) 1.70
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res (2007) 1.60
Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol (2009) 1.57
Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther (2011) 1.55
CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci (2010) 1.49
Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell (2005) 1.45
Mediation of the DCC apoptotic signal by DIP13 alpha. J Biol Chem (2002) 1.43
CaMKIIbeta association with the actin cytoskeleton is regulated by alternative splicing. Mol Biol Cell (2006) 1.39
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol (2009) 1.38
Autophagy and cancer therapy. Cancer Biol Ther (2011) 1.32
CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem (2010) 1.28
Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther (2013) 1.24
Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proc Natl Acad Sci U S A (2010) 1.24
Tyrosine dephosphorylation and ethanol inhibition of N-Methyl-D-aspartate receptor function. J Biol Chem (2003) 1.22
Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol Biol Cell (2005) 1.21
Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem (2003) 1.19
Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem (2010) 1.18
Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem (2004) 1.18
STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res (2014) 1.17
Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res (2003) 1.16
Inhibition of autophagy impairs tumor cell invasion in an organotypic model. Cell Cycle (2012) 1.14
Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. J Biol Chem (2011) 1.13
Translational evidence that impaired autophagy contributes to arterial ageing. J Physiol (2012) 1.12
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res (2005) 1.11
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res (2013) 1.06
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther (2007) 1.04
CaMKII in cerebral ischemia. Acta Pharmacol Sin (2011) 1.04
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res (2010) 1.02
The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res (2012) 1.01
Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol (2002) 1.00
alphaCaMKII autophosphorylation levels differ depending on subcellular localization. Brain Res (2007) 0.99
Regulation of HMGB1 release by autophagy. Autophagy (2009) 0.97
Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles. Mol Biol Cell (2012) 0.96
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem (2007) 0.96
Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res (2011) 0.96
Autophagy and cell death. Essays Biochem (2013) 0.95
Camkii-mediated phosphorylation regulates distributions of Syngap-α1 and -α2 at the postsynaptic density. PLoS One (2013) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Long term synaptic depression that is associated with GluR1 dephosphorylation but not alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor internalization. J Biol Chem (2008) 0.92
Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition. J Neurosci (2013) 0.92
Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One (2008) 0.92
Tyrosine phosphorylation of the N-methyl-D-aspartate receptor is enhanced in synaptic membrane fractions of the adult rat hippocampus. Brain Res Mol Brain Res (2005) 0.90
Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res (2011) 0.89
Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells. Mol Biol Cell (2003) 0.89
A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One (2012) 0.89
Regulation of the Pro-apoptotic scaffolding protein POSH by Akt. J Biol Chem (2007) 0.88
Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers. J Clin Invest (2015) 0.87
NMDA receptor trafficking at recurrent synapses stabilizes the state of the CA3 network. J Neurophysiol (2007) 0.87
Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol (2004) 0.87
Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen. J Biol Chem (2002) 0.87
Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol (2013) 0.86
Modulation of pediatric brain tumor autophagy and chemosensitivity. J Neurooncol (2011) 0.84
Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett (2009) 0.84
I think autophagy controls the death of my cells: what do I do to get my paper published? Autophagy (2011) 0.84
pRS yeast vectors with a LYS2 marker. Biotechniques (2004) 0.84
Improving a natural CaMKII inhibitor by random and rational design. PLoS One (2011) 0.83
Functional adaptation of the N-methyl-D-aspartate receptor to inhibition by ethanol is modulated by striatal-enriched protein tyrosine phosphatase and p38 mitogen-activated protein kinase. Mol Pharmacol (2011) 0.83
N terminus is essential for tropomyosin functions: N-terminal modification disrupts stress fiber organization and abolishes anti-oncogenic effects of tropomyosin-1. J Biol Chem (2004) 0.83
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem (2003) 0.82
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One (2011) 0.82
Rosiglitazone improves contextual fear conditioning in aged rats. Neuroreport (2004) 0.81
REMA: A computer-based mapping tool for analysis of restriction sites in multiple DNA sequences. J Microbiol Methods (2007) 0.80
Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol (2012) 0.79
Nuclear targeting of the CaMKII anchoring protein alphaKAP is regulated by alternative splicing and protein kinases. Brain Res (2006) 0.79
TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. J Urol (2010) 0.78
EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. J Neurooncol (2009) 0.77
Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors. Autophagy (2014) 0.77
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Exp Hematol (2002) 0.75
The use of cell microinjection for the in vivo analysis of viral transcriptional regulatory protein domains. Methods Mol Med (2007) 0.75